The HEL cell line, originating from a patient with erythroleukemia, exhibits accelerated growth in culture and displays reduced sensitivity to ruxolitinib, even when administered at doses capable of inhibiting JAK2/STAT activation.20 This evidence concerns the gene JAK2 and erythroleukemia.